MONTREAL, Oct. 17 /CNW/ - ConjuChem Biotechnologies Inc. (TSX:CJB - News) today announced that final data from its Phase I/II multiple-dose clinical study for the treatment of Type 2 diabetes using the Company's proprietary PC-DAC(TM):Exendin-4 compound confirmed the preliminary data reported on March 27, 2007. Final results demonstrated that the compound was well tolerated and effective in lowering blood glucose when administered once-weekly at each of the dosing levels tested.
